Ask VialBase
Immune peptides: adaptive vs innate

LL-37 vs Thymosin Alpha-1

Comparing LL-37 and Thymosin Alpha-1 across evidence, dosing, mechanisms, and research areas.

vs
Category
immune
immune
Molecular weight
—
3108.29 g/mol
Half-life
—
~2 hours
Admin routes
—
subcutaneous
Research areas
—
Immune modulationChronic infections (Hep B/C)Cancer immunotherapy adjunctVaccine response enhancementSepsis/critical care
Typical dosing
—
1500–3000 mcg · 2-3x weekly · 4-12 weeks
FDA status
research-only
Not FDA-approved in US. Approved in 37+ countries as Zadaxin (thymalfasin)
WADA status
—
Not listed
PubMed studies
—
857

More Comparisons

bpc-157 vs tb-500 cjc-1295 vs ipamorelin semaglutide vs tirzepatide ghk-cu vs ghk ghrp-2 vs ghrp-6 igf-1-lr3 vs igf-1-des semax vs selank epithalon vs ghk-cu bpc-157 vs ghk-cu pt-141 vs kisspeptin semaglutide vs aod-9604 tirzepatide vs mk-677 bpc-157 vs cerebrolysin tesamorelin vs cjc-1295 mk-677 vs ipamorelin mots-c vs nad-plus cerebrolysin vs semax epithalon vs nad-plus semaglutide vs retatrutide

This comparison is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before using any peptide or supplement.

Source this stack
LL-378 vetted vendors
BioLongevity LabsVisit BioLongevity Labs →

Save 15% with code VIALBASE

See all 8 sources →
Thymosin Alpha-13 vetted vendors
BioLongevity LabsVisit BioLongevity Labs →

Save 15% with code VIALBASE

See all 3 sources →

VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.